Biotech Values

[poorgradstudent]

NKTR:

Yeah, I don't think you can get overly broad use with intratumoral injection.

One thing that's a bit interesting is that nektar is heavily into the biased agonist approach. This is the general method that I generally thought / think is a bit too dependent on experimental conditions you can invoke in the lab. It's why I was negative about Trevena's CV program.